VitriVax Inc.
The University of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (51³Ô¹ÏÍø Molecular, Cellular & Developmental Biology) and Ìýat 51³Ô¹ÏÍø (51³Ô¹ÏÍø Chemical and Biological Engineering).
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech​, Manufacturing​, Therapeutics, Vaccines
- Funding Stage: Series B Round or beyond
- Contact for Investment Inquiries: Rom Colindres, CEO, rcolindres@vitrivaxbio.com
In the News
- New single-dose, temperature-stable rabies vaccines could expand global access (2025)
- (2024)
- VitriVax, a 51³Ô¹ÏÍø spinout, receives $5M grant from Gates Foundation (2023)
- VitriVax wins $29M Department of Defense contract for vaccine research (2023)
- New Buff Venture Fund makes landmark investments in 51³Ô¹ÏÍø startups (2023)
- Why developing a successful COVID-19 vaccine is only half the battle (2020)
- 51³Ô¹ÏÍø brings together top spinoffs from Colorado research institutions for Destination Startup (2019)
- State accelerator program fosters 51³Ô¹ÏÍø spin-off companies (2017)
Venture Partners Programs​
- Buff Gold Venture Fund (2023)
- Destination Startup (2019)
- Intellectual Property Management (2006)
Technology Development Funding
Gates Foundation
ÌýÌý ÌýThis page was last updated on April 14, 2025. Please email vpnews@colorado.edu for corrections or updates
Media Inquiries
For marketing and communication inquiries, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at 51³Ô¹ÏÍø.
For media inquiries, please visit .